Improving Outcomes in Post-Acute Myocardial Infarction Heart Failure: Incorporation of Aldosterone Blockade into Combination Therapy to Optimize Neurohormonal Blockade

American Journal of Cardiology

Volumn 97, Issue 10 SUPPL. 1, 2006, Pages 26-33

  Pitt, Bertram ^a   Fonarow, Gregg C ^b   Gheorghiade, Mihai ^c   Deedwania, Prakash C ^d   Duprez, Daniel A ^e  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF SAN FRANCISCO   (United States)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; FIBRINOLYTIC AGENT; FOSINOPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; METOPROLOL; METOPROLOL SUCCINATE; NEBIVOLOL; NEUROHORMONE; QUINAPRIL; RAMIPRIL; SPIRONOLACTONE; TRANDOLAPRIL; VALSARTAN;

ACUTE HEART INFARCTION; ARTICLE; CLINICAL TRIAL; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; GYNECOMASTIA; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HEART MUSCLE INJURY; HEMODYNAMICS; HORMONE ACTION; HUMAN; HYPERKALEMIA; HYPOKALEMIA; IMPOTENCE; MASTALGIA; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SURVIVAL;

ADRENERGIC BETA-ANTAGONISTS; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DRUG THERAPY, COMBINATION; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL INFARCTION; TREATMENT OUTCOME;

EID: 33646368293     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.03.006     Document Type: Article

References (40)

1. Flather M.D., Yusuf S., Køber L., Pfeffer M., Hall A., Murray G., Torp-Pedersen C., Ball S., Pogue J., Moyé L., Braunwald E., and ACE-Inhibitor Myocardial Infarction Collaborative Group. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction. a systematic overview of data from individual patients. Lancet 355 (2000) 1575-1581
2. Pfeffer M.A., Braunwald E., Moye L.A., Basta L., Brown Jr. E.J., Cuddy T.E., Davis B.R., Geltman E.M., Goldman S., Flaker G.C., et al., SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. results of the survival and ventricular enlargement trial. N Engl J Med 327 (1992) 669-677
3. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342 (1993) 821-828
4. Køber L., Torp-Pedersen C., Carlsen J.E., Bagger H., Eliasen P., Lyngborg K., Videbæk J., Cole D.S., Auclert L., Pauly N.C., and Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 333 (1995) 1670-1676
5. Dickstein K., Kjekshus J., and OPTIMAAL Steering Committee for the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction. the OPTIMAAL [Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan] randomised trial. Lancet 360 (2002) 752-760
6. Pfeffer M.A., McMurray J.J., Velazquez E.J., Rouleau J.L., Kober L., Maggioni A.P., Solomon S.D., Swedberg K., Van de Werf F., White H., et al., Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 (2003) 1893-1906
7. Gottlieb S.S., McCarter R.J., and Vogel R.A. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 339 (1998) 489-497
8. Dargie H.J. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction. the CAPRICORN randomised trial. Lancet 357 (2001) 1385-1390
9. Janosi A., Ghali J.K., Herlitz J., Czuriga I., Klibaner M., Wikstrand J., Hjalmarson A., and MERIT-HF Study Group. Metoprolol CR/XL in postmyocardial infarction patients with chronic heart failure. experiences from MERIT-HF. Am Heart J 146 (2003) 721-728
10. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., Bittman R., Hurley S., Kleiman J., Gatlin M., and Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321
11. Wu A.H., Parsons L., Every N.R., and Bates E.R. Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction. a report from the Second National Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol 40 (2002) 1389-1394
12. Hasdai D., Topol E.J., Kilaru R., Battler A., Harrington R.A., Vahanian A., Ohman E.M., Granger C.B., Van de Werf F., Simoons M.L., O'Connor C.M., and Holmes Jr. D.R. Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction. lessons from 4 international fibrinolytic therapy trials. Am Heart J 145 (2003) 73-79
13. Steg P.G., Dabbous O.H., Feldman L.J., Cohen-Solal A., Aumont M.C., Lopez-Sendon J., Budaj A., Goldberg R.J., Klein W., Anderson Jr. F.A., and Global Registry of Acute Coronary Events Investigators. Determinants and prognostic impact of heart failure complicating acute coronary syndromes. observations from the Global Registry of Acute Coronary Events (GRACE). Circulation 109 (2004) 494-499
14. Braunwald E. Normal and abnormal myocardial function. cellular basis of cardiac contraction. In: Braunwald E., Hauser S.L., Fauci A.S., Longo D.L., Kasper D.L., and Jameson J.L. (Eds). Harrison's Principles of Internal Medicine. 15th ed. (2001), McGraw-Hill, New York 1316-1318
15. Pfeffer M.A., Lamas G.A., Vaughan D.E., Parisi A.F., and Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 319 (1988) 80-86
16. Sharpe N., Murphy J., Smith H., and Hannan S. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet 1 (1988) 255-259
17. Antman E.M., Anbe D.T., Armstrong P.W., Bates E.R., Green L.A., Hand M., Hochman J.S., Krumholz H.M., Kushner F.G., Lamas G.A., et al., American College of Cardiology/American Heart Association Task Force on Practice Guidelines. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary. a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 110 (2004) 588-636
18. Hunt S.A., Abraham W.T., Chin M.H., Feldman A.M., Francis G.S., Ganiats T.G., Jessup M., Konstam M.A., Mancini D.M., Michl K., et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Circulation 112 (2005) 1825-1852
19. Swedberg K., Cleland J., Dargie H., Drexler H., Follath F., Komajda M., Tavazzi L., Smiseth O.A., Gavazzi A., Haverich A., et al., Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. executive summary (update 2005). Eur Heart J 26 (2005) 1115-1140
20. A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. JAMA 250 (1983) 2814-2819
21. Chadda K., Goldstein S., Byington R., and Curb J.D. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 73 (1986) 503-510
22. Staessen J., Lijnen P., Fagard R., Verschueren L.J., and Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 91 (1981) 457-465
23. Struthers A.D. Aldosterone blockade in cardiovascular disease. Heart 90 (2004) 1229-1234
24. Hayashi M., Tsutamoto T., Wada A., Maeda K., Mabuchi N., Tsutsui T., Matsui T., Fujii M., Matsumoto T., Yamamoto T., et al. Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction. extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol 38 (2001) 1375-1382
25. Hayashi M., Tsutamoto T., Wada A., Tsutsui T., Ishii C., Ohno K., Fujii M., Taniguchi A., Hamatani T., Nozato Y., et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 107 (2003) 2559-2565
26. Vantrimpont P., Rouleau J.L., Ciampi A., Harel F., de Champlain J., Bichet D., Moye L.A., and Pfeffer M. Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) study. Eur Heart J 19 (1998) 1552-1563
27. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., Palensky J., Wittes J., and Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 (1999) 709-717
28. Pitt B., White H., Nicolau J., Martinez F., Gheorghiade M., Aschermann M., van Veldhuisen D.J., Zannad F., Krum H., Mukherjee R., Vincent J., and EPHESUS Investigators. Eplerenone reduces mortality 30 days post-randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 46 (2005) 425-431
29. Pitt B., Gheorghiade M., Zannad F., Anderson J., van Veldhuisen D.J., Parkhomenko A., Corbalan R., Klug E.Q., Mukherjee R., Solomon H., and EPHESUS Investigators. Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction ≤30%. Eur J Heart Fail (2006) February 24 [Epub ahead of print]
30. Pitt B., Krum H., Niclau J.C., Carsoso S., Parkhomenko A., Aschermann M., Corblan R., Zannad F., Bittman R., and Kleiman J. The EPHESUS trial. effect of eplerenone in patients with a baseline history of hypertension. Circulation 108 suppl (2003) 599 Abstract 2727
31. O'Keefe J., Zarich S., Felicetta J., Patni R., Chu T.C., Solomon H., and Pitt B. Eplerenone is safe and effective in diabetic patients with post-acute myocardial infarction heart failure. results of an EPHESUS substudy. [abstract]. Diabetes 53 suppl 2 (2004) A116
32. van Veldhuisen D.J., Aschermann M., Zannad F., Krum H., Vincent J., Mukherjee R., Pitt B., and EPHESUS Investigators. Eplerenone benefit at 30 days in high-risk subgroups in the EPHESUS trial. [abstract]. Eur J Heart Fail 4 suppl 1 (2005) 79
33. Banas J., White H., Parkomenko A., Patni R., Mukherjee R., and Zannad F. Favorable outcomes with 25 mg of eplerenone in patients with post-AMI heart failure. results from the EPHESUS trial. [abstract]. J Cardiac Fail 11 suppl (2005) S156
34. Bozkurt B., Agoston I., and Knowlton A.A. Complications of inappropriate use of spironolactone in heart failure. when an old medicine spirals out of new guidelines. J Am Coll Cardiol 41 (2003) 211-214
35. Juurlink D.N., Mamdani M.M., Lee D.S., Kopp A., Austin P.C., Laupacis A., and Redelmeier D.A. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351 (2004) 543-551
36. Mehta S.R., Yusuf S., Diaz R., Zhu J., Pais P., Xavier D., Paolasso E., Ahmed R., Xie C., Kazmi K., et al., CREATE-ECLA Trial Group Investigators. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction. the CREATE-ECLA [Clinical Trial of Metabolic Modulation in Acute Myocardial Infarction Treatment Evaluation-Estudios Cardiologicos Latinoamerica] randomized controlled trial. JAMA 293 (2005) 437-446
37. Fonarow G.C., Gawlinski A., Moughrabi S., and Tillisch J.H. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol 87 (2001) 819-822
38. Ranjan A., Tarigopula L., Srivastava R.K., Obasanjo O.O., and Obah E. Effectiveness of the clinical pathway in the management of congestive heart failure. South Med J 96 (2003) 661-663
39. Fonarow G.C. Strategies to improve the use of evidence-based heart failure therapies. OPTIMIZE-HF. Rev Cardiovasc Med 5 suppl 1 (2004) S45-S54
40. Fonarow G., Abraham W.T., Albert N.M., Gattis W., Gheorghiade M., Greenberg B., O'Connor C.M., She L., Yancy C.W., and Young J.B. Does patient age impact the use of evidence-based heart failure therapies at hospital discharge? A report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). [abstract]. J Am Coll Cardiol 45 (2005) 339A